CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows from Operating Activities:
Net income (loss)	$ 63,681	$ (29,956)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)	19,331	17,956
Non-cash compensation	22,390	19,624
Amortization and impairment of operating lease right of use assets	25,720	25,427
(Gain) loss on disposal of property and equipment	(22)	346
Loss on personal care divestiture	0	2,186
Merger termination fee	0	106,000
Deferred income taxes	7,382	15,417
Equity in earnings from equity method investments	(4,316)	(9,366)
Amortization of deferred debt issuance costs	743	743
Return on equity method investments	2,160	4,309
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	11,503	(32,934)
Other current assets	11,242	(15,434)
Operating lease right of use assets	(3,135)	(2,803)
Other assets	598	273
Accounts payable	4,167	(8,839)
Accrued expenses	12,495	10,340
Other long-term obligations	(532)	(3,156)
Operating lease liabilities	(22,019)	(23,256)
Net cash provided by operating activities	151,388	76,877
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	21	25
Proceeds from the sale of property and equipment	0	100
Purchases of property and equipment	(5,440)	(3,728)
Investments in technology assets	(619)	(6,881)
Investments in equity method investees	(1,046)	0
Return of investment	0	150
Proceeds from personal care divestiture	0	47,787
Acquisitions of businesses, net of cash acquired	0	(350)
Net cash (used in) provided by investing activities	(7,084)	37,103
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	88	100
Proceeds from issuance of stock under employee stock purchase plan	0	2,602
Shares withheld to pay taxes on non-cash compensation	(4,840)	(4,413)
Noncontrolling interest contributions	1,911	1,232
Noncontrolling interest distributions	(2,574)	(1,614)
Purchase of noncontrolling interest	0	(800)
Proceeds from borrowings under revolving line of credit	0	23,000
Repayments of borrowings under revolving line of credit	0	(23,000)
Principal payments of long-term obligations	(27,730)	(67,113)
Payment of accrued contingent consideration	(4,572)	(4,091)
Net cash used in financing activities	(37,717)	(74,097)
Net increase in cash, cash equivalents and restricted cash	106,587	39,883
Cash, cash equivalents and restricted cash at beginning of period	138,863	54,133
Cash, cash equivalents and restricted cash at end of period	245,450	94,016
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	23,220	19,787
Cash paid for income taxes, net of refunds received	27,993	24,318
Cash paid for operating lease liabilities	25,154	26,059
Cash paid for finance lease liabilities	10,834	8,462
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	18,950	25,261
Right of use assets obtained in exchange for finance lease liabilities	12,228	34,964
Reductions to right of use assets resulting from reductions to operating lease liabilities	200	15,135
Reductions to right of use assets resulting from reductions to finance lease liabilities	$ 1,512	$ 1,209